58-32-2
58-32-2
Chemical Structure
Dipyridamole
- CAS No.: 58-32-2
- Formula:C24H40N8O4
- Molecular Weight:504.63
IUPAC Name: 2,2',2'',2'''-((4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol)
InChIKey: IZEKFCXSFNUWAM-UHFFFAOYSA-N
SMILES: OCCN(CCO)C1=NC(N2CCCCC2)=C(N=C(N(CCO)CCO)N=C3N4CCCCC4)C3=N1
Biological Activity: Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dipyridamole | 99.93% | Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dipyridamole (Standard) | ≥98% | Dipyridamole (Standard) is the analytical standard of Dipyridamole. This product is intended for research and analytical applications. Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dipyridamole-d20 | Dipyridamole-d20 is the deuterium labeled Dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dipyridamole-d16 | Dipyridamole-d16 is the deuterium labeled Dipyridamole. Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kerndt CC, Nagalli S. Dipyridamole. 2021 Nov 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32119342. [Content Brief]
- [2]. Longo, Joseph, etal. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Molecular oncology vol. 14,10 (2020): 2533-2545 [Content Brief]
- [3]. Wang, Jiaan-Der, etal. Exosomal HMGB1 Promoted Cancer Malignancy. Cancers vol. 13,4 877. 19 Feb. 2021. [Content Brief]
